MTOR and breast cancer: In our study, we demonstrated that the overexpression of TMEM97 in breast cancer cells contributed to resistance to tamoxifen treatment, and the overexpressed cells continuously activated the mTOR/S6K1 signaling pathway and the ERα activity.